Business
ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m
TOULOUSE, France & FULLERTON, Calif., December 16, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today announces the launch of a capital increase with the removal of preferential subscription rights ("PSR") for certain categories of persons, for an amount of nearly 1.8 million euros through the issuance of 58
About this update from Abionyx Pharma Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"Capital increase of approximately 1.8 million euros","length":51,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Subscription price: 3.10 euros","length":30,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Extension of visibility until the end of 2026","length":45,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":126,"olType":false},{"type":"text","content":"TOULOUSE, France & FULLERTON, Calif., December 16, 2025--(BUSINESS WIRE)--Regulatory News:","length":94,"tagName":"p"},{"type":"text","content":"ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today announces the launch of a capital increase with the removal of preferential subscription rights ("PSR") for certain categories of persons, for an amount of nearly 1.8 million euros through the issuance of 580,643 new shares at a subscription price of 3.10 euros (the "Issuance"). This capital increase is intended to strengthen the Company's cash position.","length":599,"tagName":"p"},{"type":"text","content":"Legal framework of the Issue","length":28,"tagName":"p"},{"type":"text","content":"This transaction is part of a capital increase with cancellation of preferential subscription rights in favor of persons belonging to specific categories, decided today by the Board of Directors, acting on the basis of the delegation granted by the fourteenth resolution of the Company's Combined Shareholders' Meeting of June 26, 2025.","length":344,"tagName":"p"},{"type":"text","content":"Terms and conditions of the Issue","length":33,"tagName":"p"},{"type":"text","content":"The Board of Directors decided today to issue a maximum number of 580,643 ordinary shares with a par value of €0.05 at a price corresponding to the closing price on the last trading day prior to the setting of the issue price, less a maximum discount of 10%. The Chief Executive Officer, acting on behalf of the Board of Directors, noted that the closing price on December 16, 2025, was 3.445 euros and set the issue price at 3.10 euros per new share.","length":451,"tagName":"p"},{"type":"text","content":"The maximum nominal amount of the capit...